GlassScriptPhysician profile
Danielle Lee Albritton
NPI 1114969151
$7,200.16
in general payments reported to CMS, 2019-2025
35 companies · $16.49 in 2025
The $16.49 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,013 · 2020: $1,237 · 2021: $1,302 · 2022: $1,095 · 2023: $1,410 · 2024: $1,126 · 2025: $16.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,553.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,277.01 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $894.76 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $703.12 | 2019-2024 | Otezla, Repatha |
| Pfizer INC. | $681.44 | 2019-2024 | |
| Lilly USA, LLC | $604.88 | 2019-2024 | Jardiance, Mounjaro, Emgality |
| Abbvie INC. | $587.12 | 2021-2024 | Ubrelvy, Vraylar, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $469.38 | 2019-2024 | Jardiance, Synjardy |
| Merck Sharp & Dohme LLC | $264.50 | 2019-2022 | |
| Amarin Pharma, INC. | $232.68 | 2019-2021 | |
| Glaxosmithkline, LLC. | $196.67 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Biohaven Pharmaceuticals, INC. | $147.54 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $138.49 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $122.42 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.49 | 2023-2024 | Xifaxan, Ibschek |
| Currax Pharmaceuticals LLC | $82.54 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $82.22 | 2022 | |
| Idorsia Pharmaceuticals US INC | $69.30 | 2023 | Quviviq |
| Almatica Pharma LLC | $60.69 | 2023 | Gralise, Loreev Xr |
| Bayer Healthcare Pharmaceuticals INC. | $54.04 | 2022-2023 | |
| Abbott Laboratories | $54.03 | 2022-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Exact Sciences Corporation | $45.92 | 2023-2024 | Cologuard Collection Kit |
| Horizon Therapeutics Plc | $42.48 | 2020 | |
| Inari Medical, INC. | $36.41 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Medtronic, INC. | $35.40 | 2021-2022 | |
| Genentech USA, INC. | $30.14 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.86 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $23.96 | 2022 | |
| Astellas Pharma US INC | $23.92 | 2021 | |
| Agios Pharmaceuticals, INC. | $21.88 | 2024 | Pyrukynd |
| Lundbeck LLC | $20.47 | 2023 | Vyepti |
| Lucid Diagnostics INC. | $19.73 | 2023 | |
| Gilead Sciences, INC. | $16.62 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.24 | 2021 | |
| Eisai INC. | $15.05 | 2020 | |
| Ethicon US, LLC | $11.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Albritton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.